Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

0.9600 -0.0329 (-3.31%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Reports Second Quarter 2022 Financial Results
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Appoints James Ahlers as Chief Financial Officer
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Launches “The RenovoRx Story” Video Series
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform’s Potential Utility for the Treatment of Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Reports First Quarter 2022 Financial Results
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Reports Full Year 2021 Financial Results
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference
From RenovoRx, Inc.
Via Business Wire
News headline image
RenovoRx Announces Third Quarter 2021 Financial Results
From RenovoRx
Via Business Wire
News headline image
RenovoRx Announces Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting
From RenovoRx, Inc.
Via Business Wire
News headline image
Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
InvestorNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Closes $16.7M IPO
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.